Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy

Robert G. Masterton*, A. Galloway, G. French, M. Street, J. Armstrong, E. Brown, J. Cleverley, P. Dilworth, Carole Fry, A. D. Gascoigne, Alan Knox, Dilip Nathwani, Robert Spencer, Mark Wilcox

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    259 Citations (Scopus)


    These evidence-based guidelines have been produced after a systematic literature review of a range of issues involving prevention, diagnosis and treatment of hospital-acquired pneumonia (HAP). Prevention is structured into sections addressing general issues, equipment, patient procedures and the environment, whereas in treatment, the structure addresses the use of antimicrobials in prevention and treatment, adjunctive therapies and the application of clinical protocols. The sections dealing with diagnosis are presented against the clinical, radiological and microbiological diagnosis of HAP. Recommendations are also made upon the role of invasive sampling and quantitative microbiology of respiratory secretions in directing antibiotic therapy in HAP/ventilator-associated pneumonia.

    Original languageEnglish
    Pages (from-to)5-34
    Number of pages30
    JournalJournal of Antimicrobial Chemotherapy
    Issue number1
    Publication statusPublished - Jul 2008

    Bibliographical note

    Funding Information:
    A. G. has received funds for speaking at a symposium organized on behalf of Wyeth Pharmaceuticals Ltd. R. S. has received personal remuneration for speaking at an educational meeting organized by Wyeth. R. G. M. has received speaker honoraria from AstraZeneca and Wyeth. D. N. presently is a member of a number of UK and European Pharmaceutical Advisory boards (tigecycline, Wyeth; ceftobiprole, Janssen-Cilag; daptomycin, Novartis; linezolid, Pfizer; and OPT-80, Optimer). He has received honoraria to speak at meetings organized by Pfizer, Wyeth and Novartis. M. W. has received honoraria for consultancy work, financial support to attend meetings and research funding from AstraZeneca, Bayer, Genzyme, Nabriva, Pfizer, Vicuron and Wyeth. A. D. G. and M. S. have received funds for speaking at symposia organized on behalf of Wyeth and E. B. has received fees for speaking at a symposium sponsored by Novartis and for being a member of advisory panels for Chiron, Novartis and Janssen-Cilag. He has also received sponsorship from Chiron to attend a conference. J. A., A. K., G. F., P. D., J. C. and C. F. have none to declare.

    Funding Information:
    We would like to acknowledge Corvus Communications Ltd and particularly Alison Crowe and Alistair Knight from within that company. Corvus Communications Ltd acted as the secretariat throughout this project and their support was from an unrestricted educational grant from Wyeth Pharmaceuticals Ltd, to whom we are also grateful for such funding.


    • Antimicrobial treatment
    • Diagnosis
    • Evidence-based guidelines
    • Healthcare-associated pneumonia
    • Hospital-acquired pneumonia
    • Prevention


    Dive into the research topics of 'Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the working party on hospital-acquired pneumonia of the british society for antimicrobial chemotherapy'. Together they form a unique fingerprint.

    Cite this